NCT03023319View on ClinicalTrials.gov

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

May 10, 2022

Study Completion Date

May 10, 2022

Conditions
Carcinoma, Non-Small-Cell LungMesotheliomaBladder CancerOvarian CancerPeritoneal CancerThymomaThymus CancerUterine Cervical Cancer
Interventions
DRUG

Bosutinib

100mg daily for 4 cycles (21 days per cycle)

DRUG

Pemetrexed

500 mg/m2 every 21 days for 4 cycles

Trial Locations (1)

30912

Augusta University Georgia Cancer Center, Augusta

All Listed Sponsors
lead

Nagla Abdel Karim

OTHER

NCT03023319 - Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter